Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 10th International Conference on Cancer Stem Cells and Oncology Research London, UK.

Day 1 :

Keynote Forum

Michael Retsky

Harvard TH Chan School of Public Health, USA

Keynote: Perioperative use of NSAID might prevent early relapses in breast and other cancers: An upstream approach

Time : 09:00-09:40

OMICS International Oncology Research 2017 International Conference Keynote Speaker Michael Retsky photo

Michael Retsky (PhD in Physics from University of Chicago) made a career change to cancer research thirty years ago.  He was on Judah Folkman’s staff at Harvard Medical School for 12 years. Retsky is Editor of a Nature/Springer book on breast cancer to be published in 2017. He is a founder and on the Board of Directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending on treatment of early stage cancer.


A bimodal pattern of hazard of relapse among early stage breast cancer patients has been identified in multiple databases from US, Europe and Asia. We are studying these data to determine if this can lead to new ideas on how to prevent relapse in breast cancer.  Using computer simulation and access to a very high quality database from  Milan for patients treated with mastectomy only, we proposed that relapses within 3 years of surgery are stimulated somehow by the surgical procedure. Most relapses in breast cancer are in this early category. Retrospective data from a Brussels anesthesiology group suggests a plausible mechanism. Use of ketorolac, a common NSAID analgesic used in surgery was associated with far superior disease-free survival in the first 5 years after surgery. The expected prominent early relapse events in months 9-18 are reduced 5-fold. Transient systemic inflammation accompanying surgery (identified by IL-6 in serum) could facilitate angiogenesis of dormant micrometastases, proliferation of dormant single cells, and seeding of circulating cancer stem cells (perhaps in part released from bone marrow) resulting in early relapse and could have been effectively blocked by the perioperative anti-inflammatory agent. If this observation holds up to further scrutiny, it could mean that the simple use of this safe, inexpensive and effective anti-inflammatory agent at surgery might eliminate early relapses. We suggest this would be most effective for triple negative breast cancer and be especially valuable in low and middle income countries. Similar bimodal patterns have been identified in other cancers suggesting a general effect.

Keynote Forum

Karol Sikora

Proton Partners International Limited, UK

Keynote: The future place of protons in radiotherapy

Time : 09:40-10:20

OMICS International Oncology Research 2017 International Conference Keynote Speaker Karol Sikora photo

Karol Sikora is Chief Medical Officer of Proton Partners International. He was the founder of Cancer Partners UK which has created UK’s largest independent UK cancer network with private equity. He was Professor and Chairman of the Department of Cancer Medicine at Imperial College School of Medicine and is still honorary Consultant Oncologist at Hammersmith Hospital, London. He is Dean and Professor of Medicine at Britain’s first independent Medical School at the University of Buckingham and a Fellow of Corpus Christi College, Cambridge. He has published over 300 papers and written or edited 20 books including Treatment of Cancer - the standard British postgraduate textbook, now in its sixth edition. His new book for patients The street-wise patient’s guide to cancer survival has just been published.


Meaningful large scale randomized trials with protons versus photons are unlikely. Instead the pre-treatment comparison of PBT versus IMRT in individual patients using pre-set metrics of plan quality will be necessary for funding. This assessment would be made objectively by treatment planning software systems. Payers, both government and insurers, will use these criteria to assess the value of PBT in an individual using a comparative equation incorporating tumor control, late toxicity and overall lifetime costs of care. Such analyses will determine the level of the therapeutic plateau in the relationship of cost to clinical outcome gain. The range of published estimates varies enormously from 1.5% (UK, NHS) to 20% in the US. The majority of European strategic plans are assuming a 10-15% utilization of protons in patients treated with radical radiotherapy.

Keynote Forum

Diana Anderson

University of Bradford, UK

Keynote: An empirical assay for assessing genomic sensitivity and for improving cancer diagnostics

Time : 10:30-11:10

OMICS International Oncology Research 2017 International Conference Keynote Speaker Diana Anderson photo

Diana Anderson holds the established Chair in Biomedical Sciences at the University of Bradford. She obtained her first degree in the University of Wales and second degrees in the Faculty of Medicine, University of Manchester. She has 450+ peer-reviewed papers, 9 books, has successfully supervised 29 PhDs, and been a Member of Editorial Boards of 10 international journals. She has been or is Editor in Chief of a book Series on toxicology for J. Wiley and sons and the Royal Society of Chemistry respectively. She gives key note addresses at various international meetings. She is a consultant for many international organizations, such as the WHO, NATO, TWAS, UNIDO and the OECD. 


Detection tests have been developed for many cancers, but there is no single test to identify cancer in general. We have developed such an assay. In this modified patented comet assay, we investigated peripheral lymphocytes of 208 individuals: 20 melanoma, 34 colon cancer, 4 lung cancer patients 18 suspect melanoma, 28 polyposis, 10 COPD patients and 94 healthy volunteers. The natural logarithm of the olive tail moment was plotted for exposure to UVA through different agar depths for each of the above groups and analyzed using a repeated measures regression model. Response patterns for cancer patients formed a plateau after treating with UVA where intensity varied with different agar depths. In comparison, response patterns for healthy individuals returned towards control values and for pre/suspected cancers were intermediate with less of a plateau. All cancers tested exhibited comparable responses. Analyses of receiver operating characteristic curves, of mean log olive tail moments, for all cancers plus pre/suspected-cancer versus controls gave a value for the area under the curve of 0.87; for cancer versus pre/suspected-cancer plus controls the value was 0.89 and for cancer alone versus controls alone (excluding pre/suspected-cancer), the value was 0.93. By varying the threshold for test positivity, its sensitivity or specificity can approach 100% whilst maintaining acceptable complementary measures. Evidence presented indicates that this modified assay shows promise as both a stand-alone test and as a possible adjunct to other investigative procedures, as part of detection programmes for a range of cancers.

OMICS International Oncology Research 2017 International Conference Keynote Speaker Swee T Tan photo

Dr Tan is the Director of the Gillies McIndoe Research Institute in Wellington, New Zealand. He completed medical training at Melbourne University in 1985, plastic surgery training in New Zealand in 1992, and gained a PhD from Otago University in 2001. In 1995, he was appointed Consultant Plastic & Cranio-Maxillofacial Surgeon at the Wellington Regional Plastic, Maxillofacial & Burns Unit at Hutt Hospital, where was the Director of Plastic Surgery 2000-2006 and Director of Surgery 2007-2013. He was appointed Professor in Plastic Surgery at Otago University in 2008. He is the Founder and Director of the Centre for the Study & Treatment of Vascular Birthmarks, a national referral centre. He has received numerous honours and awards and is well known internationally for his research into the stem cell basis of diseases including vascular anomalies and cancer. He is an author of over 140 publications and has delivered over 350 lectures at conferences.


Squamous cell carcinoma (SCC) makes up more than 90% of cancer affecting the oral cavity including the oral tongue, buccal mucosa, floor of mouth, retromolar trigone, hard palate, alveolus and the lip. Treatment of oral cavity SCC (OCSCC) typically involves surgical resection, often followed by radiotherapy, and sometimes biologic agents. Despite this radical treatment, the 5-year survival rate for SCC affecting most oral cavity subsites has remained at 50% for the past 4 decades. Cancer stem cells (CSCs) have been identified in many types of cancers including OCSCC. Our recent data demonstrates the presence of 3 different putative CSC subpopulations within SCC of the oral tongue, buccal mucosa and lip. We have also demonstrated these CSC subpopulations express components of the renin-angiotensin system (RAS). We ahve also shown that the CSCs in one of these cancers studied (oral tongue SCC) also express the protease cathepsins B, D and G (CathG), suggesting the existence of potential bypass loops for the RAS. Our work suggests CSCs as a novel therapeutic target by modulation of the RAS using existing medications.

Keynote Forum

John Batchelor

Central Manchester Foundation Trust Manchester, UK

Keynote: The pathogenesis of spontaneous intracranial hemorrhage in patients with haematological malignancy

Time : 11:50-12:30

OMICS International Oncology Research 2017 International Conference Keynote Speaker John Batchelor photo

John Batchelor is currently Consultant in Emergency Medicine at Central Manchester Foundation Trust, England UK. He is also Honorary Lecturer at Manchester Metropolitan University. He is graduated from Leeds University England in 1982. He is a Fellow of the Royal College of Surgeons of Ireland and Fellow of the Faculty of Emergency Medicine of England. He undertook his MD thesis at University College London. He has written extensively on the subject of minor head injuries. He has presented a paper in Paris in 2012 on a meta-analysis looking at the relationship between cerebral micro bleeds and antiplatelet agents. He has also recently published a meta-analysis on the effect on mortality of platelet transfusions in adults with spontaneous or traumatic antiplatelet associated intracranial hemorrhage. His current research interest lies in the area of risk factors for intracranial hemorrhage in both adults and paediatrics secondary to coagulopathy and thrombocytopenia. 


Spontaneous intracranial hemorrhage is a well-recognized complication in patients with haematological disease. Intracranial hemorrhage is the second leading cause of death in patients with acute myeloid leukemia. The reported mortality is over 50% for patients with haematological malignancy and spontaneous intracranial hemorrhage. The reported incidence of spontaneous intracranial hemorrhage appears to be slightly higher in acute myeloid leukemia (AML) and chronic myeloid leukemia in blast crisis than in other forms of homological malignancy. The distribution of ICH is as follows: Intraparenchymal hemorrhage accounts for about 60% of the reported case series. The remaining sites are distributed between the cerebellum, brainstem, and basal ganglia, subarachnoid, subdural, interventricular and epidural regions. Over 50% of patients will be having more than one intracranial bleeding site on CT. Previously proposed risk factors for spontaneous intracranial bleeding includes: Direct invasion by tumor cells, invasive intracranial sepsis, hyper leukocytosis, and coagulopathy. Abnormalities of clotting include DIC, thrombocytopenia and prolonged prothrombin time. Coagulopathy and thrombocytopenia are probably not the main factors responsible for spontaneous intracranial hemorrhage in view of the fact that neither platelets nor clotting factors are responsible for maintaining cerebral vessel integrity under normal physiological conditions. Cohort studies from patients with idiopathic thrombocytopenia have shown a poor correlation between platelet count and the risk of spontaneous intracranial hemorrhage in both adults and children. Batchelor (2015) has shown that coagulopathy in patients with traumatic intracranial bleeding increases the risk of progressive hematoma progression by an odds ratio of 6.176 (95% CI: 4.727–8.069). This paper will explore other factors which may account for spontaneous ICH in patients with haematological malignancy. This paper will also explore the threshold for platelet transfusions in patients with haematological malignancy and thrombocytopenia based upon the current evidence.